Vulvar carcinoma: a retrospective analysis of 80 patients

• Published in: Archives of gynecology and obstetrics Vol. 262; no. 3-4; pp. 99 - 104
• Main Authors: Wagner, W, Prott, F J, Weissmann, J, Niewöhner-Desbordes, U, Ostkamp, K, Alfrink, M
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 01.03.1999
• Subjects: Adenocarcinoma - diagnosis; Adenocarcinoma - mortality; Adenocarcinoma - therapy; Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - therapy; Combined Modality Therapy; Female; Genital cancers; Humans; Middle Aged; Prognosis; Radiation therapy; Radiotherapy - adverse effects; Retrospective Studies; Survival Rate; Treatment Outcome; Vulvar Neoplasms - diagnosis; Vulvar Neoplasms - mortality; Vulvar Neoplasms - therapy
• ISSN: 0932-0067; 1432-0711
• DOI: 10.1007/s004040050236

We evaluated the files of 80 women who were treated for vulvar carcinoma. In 13 women radiotherapy was used as primary treatment, in 45 cases postoperatively and in 22 women because of local recurrence. Patients older than 60 years had a significantly worse 5-year survival rate (39%) than younger women (57%) (p = 0.02). The 5-year survival rate for patients with negative nodes was 72% versus 46% for the N1- and 47% for the N2-status, respectively (p = 0.027). The 5-year actuarial survival rate for patients with tumor manifestation in the clitoris was 77.9% versus 26.1% for patients with tumors in the labia majora (p = 0.0044). There was no difference in survival in patients who had been treated with radical vulvectomy and bilateral groin dissection plus local radiotherapy when compared with patients who had been irradiated (whole pelvis) after tumor resection alone. The 5-year survival rates and the median survival time were identical in both groups (61%/62 months).